150 related articles for article (PubMed ID: 37851143)
1. Efficacy of fosaprepitant combined with tropisetron plus dexamethasone in preventing nausea and emesis during fractionated radiotherapy with weekly cisplatin chemotherapy: interim analysis of a randomized, prospective, clinical trial using competing risk analysis.
Xie S; Huang R; Zhan Y; Cai Q; Wu Y; Huang K; Lin X; Wang R; Yan Y; Xie R; Wang S; Zeng C; Chen C
Support Care Cancer; 2023 Oct; 31(12):640. PubMed ID: 37851143
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial.
Ruhlmann CH; Christensen TB; Dohn LH; Paludan M; Rønnengart E; Halekoh U; Hilpert F; Feyer P; Kristensen G; Hansen O; Keefe D; Herrstedt J
Lancet Oncol; 2016 Apr; 17(4):509-518. PubMed ID: 26952945
[TBL] [Abstract][Full Text] [Related]
3. Fosaprepitant Weekly vs Every 3 Weeks for the Prevention of Concurrent Chemoradiotherapy-Induced Nausea and Vomiting: A Pilot Randomized Clinical Trial.
Yang Q; Zou X; Xie YL; Lin C; Ouyang YF; Liu YL; Duan CY; You R; Liu YP; Liu RZ; Huang PY; Guo L; Hua YJ; Chen MY
JAMA Netw Open; 2023 Jul; 6(7):e2326127. PubMed ID: 37498596
[TBL] [Abstract][Full Text] [Related]
4. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
Sorbe BG
Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
[TBL] [Abstract][Full Text] [Related]
5. An open multicentre study of tropisetron for cisplatin-induced nausea and vomiting.
Olver IN; Craft PS; Clingan PR; Kearsley JH; Planner RS; van Hazel GA; Bell DR; Adena MR; Hall BE; Pearson LL
Med J Aust; 1996 Mar; 164(6):337-40. PubMed ID: 8606657
[TBL] [Abstract][Full Text] [Related]
6. The Efficacy of Palonosetron Plus Dexamethasone in Preventing Chemoradiotherapy-induced Nausea and Emesis in Patients Receiving Daily Low-dose Cisplatin-based Concurrent Chemoradiotherapy for Uterine Cervical Cancer: A Phase II Study.
Mitsuhashi A; Usui H; Nishikimi K; Yamamoto N; Hanawa S; Tate S; Watanabe-Nemoto M; Uno T; Shozu M
Am J Clin Oncol; 2017 Apr; 40(2):118-121. PubMed ID: 25144265
[TBL] [Abstract][Full Text] [Related]
7. Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study.
Gao J; Zhao J; Jiang C; Chen F; Zhao L; Jiang Y; Li H; Wang W; Wu Y; Jin Y; Da L; Liu G; Zhang Y; Li H; Zhang Z; Jin G; Li Q
Support Care Cancer; 2022 Jul; 30(7):6225-6232. PubMed ID: 35449368
[TBL] [Abstract][Full Text] [Related]
8. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.
Bruntsch U; Drechsler S; Eggert J; Gosse H; Ukena D; Imhoff W; Faerber L
Semin Oncol; 1994 Oct; 21(5 Suppl 9):7-11. PubMed ID: 9113120
[TBL] [Abstract][Full Text] [Related]
9. Multiple-day administration of fosaprepitant combined with tropisetron and olanzapine improves the prevention of nausea and vomiting in patients receiving chemotherapy prior to autologous hematopoietic stem cell transplant: a retrospective study.
Ye P; Pei R; Wang T; Cao J; Zhang P; Chen D; Liu X; Du X; Li S; Tang S; Hu Y; Jiang L; Lu Y
Ann Hematol; 2022 Aug; 101(8):1835-1841. PubMed ID: 35668198
[TBL] [Abstract][Full Text] [Related]
10. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
Piechotta V; Adams A; Haque M; Scheckel B; Kreuzberger N; Monsef I; Jordan K; Kuhr K; Skoetz N
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012775. PubMed ID: 34784425
[TBL] [Abstract][Full Text] [Related]
11. Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
Weibel S; Rücker G; Eberhart LH; Pace NL; Hartl HM; Jordan OL; Mayer D; Riemer M; Schaefer MS; Raj D; Backhaus I; Helf A; Schlesinger T; Kienbaum P; Kranke P
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012859. PubMed ID: 33075160
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study.
Chua DT; Sham JS; Kwong DL; Kwok CC; Yue A; Foo YC; Chan R
Am J Clin Oncol; 2000 Apr; 23(2):185-91. PubMed ID: 10776982
[TBL] [Abstract][Full Text] [Related]
13. Tropisetron alone or in combination with dexamethasone for the prevention and treatment of emesis induced by non-cisplatin chemotherapy: a randomized trial.
Adams M; Soukop M; Barley V; Yosef H; Anderson H; Boesen E; Trask CW; Rüfenacht E; de Bruijn KM
Anticancer Drugs; 1995 Aug; 6(4):514-21. PubMed ID: 7579555
[TBL] [Abstract][Full Text] [Related]
14. Study of efficacy and tolerability of tropisetron in the prevention of cisplatin induced nausea and vomiting.
Chiersilpa A; Ngow J
J Med Assoc Thai; 1999 Sep; 82(9):915-21. PubMed ID: 10561949
[TBL] [Abstract][Full Text] [Related]
15. The antiemetic efficacy of tropisetron plus dexamethasone as compared with conventional metoclopramide-dexamethasone combination in Orientals receiving cisplatin chemotherapy: a randomized crossover trial.
Chua DT; Sham JS; Au GK; Choy D; Kwong DL; Yau CC; Cheng AC
Br J Clin Pharmacol; 1996 May; 41(5):403-8. PubMed ID: 8735681
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacy of tropisetron versus a metoclopramide cocktail based on the intensity of cisplatin-induced emesis.
Chang TC; Hsieh F; Lai CH; Tseng CJ; Cheng HH; Li CL; Michael BJ; Soong YK
Cancer Chemother Pharmacol; 1996; 37(3):279-85. PubMed ID: 8529290
[TBL] [Abstract][Full Text] [Related]
17. Prospective randomized comparison of tropisetron with and without dexamethasone against high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting.
Malik I; Moid I; Khan Z; Hussain M
Am J Clin Oncol; 1999 Apr; 22(2):126-30. PubMed ID: 10199444
[TBL] [Abstract][Full Text] [Related]
18. A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis.
Madej G; Krzakowski M; Pawinski A; Lasota W; Rogowski W; Skoneczna I
Semin Oncol; 1994 Oct; 21(5 Suppl 9):3-6. PubMed ID: 9113119
[TBL] [Abstract][Full Text] [Related]
19. Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin.
Zhao Y; Zhao B; Chen G; Chen Y; Liao Z; Zhang H; Feng W; Li Y; Weng H; Li W; Zhou Y; Ren B; Lu Y; Chen J; Liu Z; Su Z; Wang W; Zhang L
Cancer Commun (Lond); 2023 Feb; 43(2):246-256. PubMed ID: 36545810
[TBL] [Abstract][Full Text] [Related]
20. Palonosetron and prednisolone for the prevention of nausea and emesis during fractionated radiotherapy and 5 cycles of concomitant weekly cisplatin-a phase II study.
Ruhlmann CH; Belli C; Dahl T; Herrstedt J
Support Care Cancer; 2013 Dec; 21(12):3425-31. PubMed ID: 23949739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
